Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer
Cell · 2026-09 · 189 (18) · 5688-5705.e13
DOI: 10.1016/j.cell.2026.07.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2026-09. Verfasst von YaTing Wen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Frontier Innovation Center, Department of Immunology, School of Basic Medical Sciences, State Key Laboratory of Systems Medicine for Cancer, Shanghai…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Receptor, Serotonin, 5-HT2A, Serotonin 5-HT2 Receptor Agonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Key Research and Development Program of China Stem Cell and Translational Research, Science and Technology Commission of Shanghai Municipality, Program of Shanghai Academic Research Leader.
Abstract (Originalsprache)
Cancer remains a leading cause of morbidity and mortality worldwide. While classical psychedelics have been used clinically to treat cancer-associated psychiatric disorders, their impact on tumor progression is unclear. Here, we show that by targeting the serotonin receptor 5-HT2AR, lysergic acid diethylamide (LSD) enhances CD8+ T cell-mediated antitumor immunity and suppresses colorectal cancer (CRC) growth. To harness this activity while avoiding psychedelic effects, we developed IHCH-8110, a non-brain-penetrant 5-HT2AR agonist that selectively targets peripheral 5-HT2AR. We show that IHCH-8110 inhibits CRC progression by activating 5-HT2AR on enteric glial cells, thereby inducing CXCL10 and interleukin (IL)-18 expression to promote CD8+ T cell recruitment and effector polarization within the tumor microenvironment. By converting immune-cold CRC into a more immunologically responsive state, IHCH-8110 enhances the efficacy of PD-1 blockade. Together, our findings identify enteric 5-HT2AR signaling as a regulator of antitumor immunity and support peripheral 5-HT2AR agonists as a therapeutic strategy for CRC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Frontier Innovation Center, Department of Immunology, School of Basic Medical Sciences, State Key Laboratory of Systems Medicine for Cancer, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Fudan Univer…
- Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shangha…
- iHuman Institute and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou…
- Department of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
Förderung
- National Key Research and Development Program of China Stem Cell and Translational Research
- Science and Technology Commission of Shanghai Municipality
- Program of Shanghai Academic Research Leader
- National Natural Science Foundation of China
Zitieren
APA
Wen, Y., Tang, L., Duan, W., Ren, Q., Ni, Y., Chen, S., Chen, J., Yang, L., Wang, H., Chen, Y., Zheng, Y., Pan, X., Du, H., Huang, M., Zeng, A., Zhou, Z., Zhang, Z., Ji, H., Ge, G., …, & Chen, J. (2026). Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer. Cell, 189(18), 5688-5705.e13. https://doi.org/10.1016/j.cell.2026.07.028
Vancouver
Wen Y, Tang L, Duan W, Ren Q, Ni Y, Chen S, et al. Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer. Cell. 2026;189(18):5688-5705.e13. doi:10.1016/j.cell.2026.07.028
BibTeX
@article{Wen2026,
author = {Wen, YaTing and Tang, LingJie and Duan, WenWen and Ren, QingFei and Ni, YangYue and Chen, ShiYang and Chen, Jun and Yang, Lei and Wang, Huan and Chen, Yuan and Zheng, YunZhe and Pan, XingChao and Du, Hui and Huang, MengWen and Zeng, An and Zhou, Zhaocai and Zhang, ZhiGang and Ji, HongBin and Ge, GaoXiang and Zeng, Yi Arial and Zhang, Wei and Wang, ShiHui and Cheng, JianJun and Wang, Sheng and Chen, JianFeng},
title = {Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer},
journal = {Cell},
year = {2026},
volume = {189},
number = {18},
pages = {5688--5705.e13},
doi = {10.1016/j.cell.2026.07.028}
}
EUVIMED